Clinical Trial

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

Study acronym: CONSOLIdATE-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-30; most recent amendment 2026-06-09.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07048457
Lead Sponsor Yale University
Collaborators: Medical College of Virginia Foundation
Conditions Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
Enrollment 32 participants
Start Date 2025-11-26
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-10